Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MITF | O75030 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881496 | 1.00 | MEN1 (0.54) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL5715919 | 0.86 | NPC1 (0.53) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL5715915 | 0.86 | NPC1 (0.53) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL4908916 | 0.86 | MAPT (0.48) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL4908928 | 0.86 | MAPT (0.48) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL4883234 | 0.82 | ALDH1A1 (0.54) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL4883238 | 0.82 | ALDH1A1 (0.54) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL4881832 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL4881835 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL11847100 | 0.82 | KMT2A (0.59) | MEN1KMT2APOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227787-A1 | Use of New Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2008-09-18 | — | — | US | disclosed |
| EP-1725227-A1 | USE OF NEW LIPOXYGENASE INHIBITORS | Biolipox AB (SE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005084656-A1 | USE OF NEW LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227787-A1 | Use of New Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | MEN1 4240/4885KMT2A 3684/4885POLB 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.